FDA Launches Rare Disease Framework Initiative, Seeks Public Input at October 28 Meeting

PHARMA REGULATION · RARE DISEASE REGULATION · OCTOBER 22, 2026 · UNITED STATES

The FDA on October 14, 2026, announced the Rare Disease Framework Initiative to “reimagine the development of drugs and biologics for rare diseases.” As outlined in a new white paper, “A New Framework for Rare Disease Review,” the Initiative will develop a fit-for-purpose framework that considers “the nuances of each disease, patient needs, product type” and the evidence that can realistically be generated in small patient populations. The agency said only “5% or so of rare conditions” have an FDA-approved treatment.

The Initiative is led by the FDA’s Rare Disease Innovation Hub, working with the Office of the Commissioner, the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). The FDA will host a public meeting on October 28 at its White Oak campus, facilitated by the Reagan-Udall Foundation for the FDA. The resulting framework “might include potential new or revised guidance, revisions to regulations, staff training, and organizational changes,” the agency said. “This new framework will enhance consistency and predictability for both sponsors and for patients,” said Amy Comstock Rick, director of the Rare Disease Innovation Hub.

The Initiative is the latest layer in a set of rare disease programs the FDA has assembled in rapid succession. In September 2025, the agency introduced Rare Disease Evidence Principles (RDEP), a program under which CDER and CBER plan to accept evidence from single-arm clinical trials — supported by natural history studies and case reports — as sufficient to meet the threshold for substantial evidence of effectiveness, according to BioPharma Dive’s reporting on the agency announcement. RDEP generally applies to conditions affecting fewer than 1,000 people in the United States and driven by a known genetic defect. In February 2026, the FDA released draft guidance fleshing out a ‘plausible mechanism pathway’ for individualized genetic medicines — therapies so targeted that traditional randomized controlled trials are often not feasible, as Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. put it, per BioPharma Dive.

Then-FDA Commissioner Marty Makary, in a statement accompanying the September 2025 RDEP release, said the principles ‘ensure that FDA and sponsors are aligned on a flexible, common-sense approach within our existing authorities, and that we incorporate confirmatory evidence to give sponsors a clear, rigorous path to bring safe and effective treatments to those who need them most.’ Kennedy said at the February 2026 event that ‘for ultra-rare conditions, randomized control trials are often — and mostly always — just not feasible,’ and that under the new framework ‘one well-controlled clinical investigation, supported by confirmatory evidence, can support approval.’

A pricing environment that shapes every approval

The regulatory liberalization is unfolding against a pricing backdrop that gives it commercial as well as clinical significance. The median annual list price for a new drug in the United States exceeded $370,000 in 2024, according to a Reuters analysis — more than double the $180,000 median recorded in 2021 for drugs first marketed through mid-July of that year, per a study published in JAMA and cited by Reuters. Reuters reported median launch prices of $300,000 in 2023 and $222,000 in 2022. The share of new drugs launched for orphan diseases (those affecting fewer than 200,000 Americans) rose to 72% in 2024 from 51% in 2019, according to the IQVIA Institute for Human Data Science, as cited by Reuters.

The interaction between flexible approval standards and this pricing environment is the structural tension the FDA’s evolving rare disease architecture will need to navigate. Each pathway that reduces the evidentiary burden for rare disease approval may also reduce the commercial risk of targeting ultra-rare populations, at a time when Reuters found median launch prices had more than doubled from 2021 levels amid a growing focus on rare disease. The FDA granted accelerated approval to Stealth BioTherapeutics’ elamipretide (Forzinity), the first treatment for Barth syndrome, on September 19, 2025, even though eight agency reviewers recommended against approval; urgent patient need and some signs of improved motor skills drove the decision, according to Reuters. The drug is priced at up to nearly $800,000 a year. That case illustrates the live tension between the agency’s flexibility mandate and its internal evidentiary standards.

What the framework adds — and what it does not yet resolve

The RDEP program and the February 2026 draft guidance on personalized therapies predate the new Initiative. The Rare Disease Innovation Hub, announced by the FDA in July 2024 as a CDER–CBER “single point of connection and engagement with the rare disease community,” now leads the new Initiative.

The principal friction point is the gap between regulatory flexibility and post-approval evidence generation. RDEP allows approval on one adequate and well-controlled study plus robust confirmatory evidence, and accelerated approvals carry post-approval study requirements — a mechanism that has historically proven difficult to enforce. The FDA’s approval of elamipretide over reviewer objections, with a four-year follow-up study required as part of its accelerated approval, is a recent illustration of how that gap can widen between the approval decision and the evidentiary record. For payers and formulary decision-makers, a drug approved on a single-arm trial with natural history support, at a list price approaching $800,000, presents a coverage assessment challenge that the new framework does not directly address.

The deeper signal in this sequence of initiatives is that the FDA is not simply lowering the bar for rare disease approvals — it is attempting to construct a differentiated evidentiary architecture in which the bar is calibrated to the size and nature of the patient population. Whether that architecture holds under the combined pressure of pricing scrutiny, payer resistance, and internal reviewer dissent is the question these overlapping initiatives have opened, not answered.

Sources: Reuters analysis (2025-05-22); Reuters (2025-11-05); FDA (2025-09-03); BioPharma Dive (2025-09-04)

Why this is relevant

Sources: FDA: FDA Launches the Rare Disease Framework Initiative (October 14, 2026) · FDA: Rare Disease Evidence Principles · BioPharma Dive: FDA outlines new review pathway for ultra-rare diseases · BioPharma Dive: FDA fleshes out new roadmap for testing personalized therapies · Reuters: Prices for new US drugs doubled in 4 years · Reuters: FDA cleared pricey rare disease drug over reviewer objections